Compare DBRG & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBRG | HAE |
|---|---|---|
| Founded | 1991 | 1971 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | 1996 |
| Metric | DBRG | HAE |
|---|---|---|
| Price | $15.77 | $75.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $16.00 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 2.9M | 972.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $373.39 | N/A |
| Revenue Next Year | $8.23 | $5.23 |
| P/E Ratio | $252.25 | ★ $36.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.94 | $47.32 |
| 52 Week High | $15.82 | $87.32 |
| Indicator | DBRG | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 54.75 |
| Support Level | $15.33 | $72.04 |
| Resistance Level | $15.82 | $80.90 |
| Average True Range (ATR) | 0.05 | 2.53 |
| MACD | -0.00 | -0.65 |
| Stochastic Oscillator | 54.17 | 25.19 |
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.